Stockscreener 앱 받기
2.23
0.89%
-0.02
시간 외 거래:
2.20
-0.03
-1.35%
전일 마감가:
$2.25
열려 있는:
$2.2
하루 거래량:
719.24K
Relative Volume:
0.81
시가총액:
$196.34M
수익:
$70.14M
순이익/손실:
$-76.24M
주가수익비율:
-2.009
EPS:
-1.11
순현금흐름:
$-57.06M
1주 성능:
-5.91%
1개월 성능:
-12.89%
6개월 성능:
-59.67%
1년 성능:
-28.98%
1일 변동 폭
$2.17
$2.3492
1주일 범위
$2.17
$2.5091
52주 변동 폭
$1.90
$6.08
Codexis Inc Stock (CDXS) Company Profile
명칭
Codexis Inc
전화
650-421-8100
주소
200 PENOBSCOT DRIVE, REDWOOD CITY, CA
CDXS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CDXS
Codexis Inc
|
2.23 | 196.34M | 70.14M | -76.24M | -57.06M | -1.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.45 | 115.69B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
529.24 | 53.25B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
307.99 | 39.22B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
577.89 | 35.78B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
269.63 | 27.68B | 3.81B | -644.79M | -669.77M | -6.24 |
Codexis Inc Stock (CDXS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-08-19 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2024-06-03 | 재개 | Jefferies | Buy |
| 2024-05-30 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-02-29 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2023-11-07 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2023-08-07 | 다운그레이드 | TD Cowen | Outperform → Market Perform |
| 2023-05-09 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2022-03-31 | 재개 | Piper Sandler | Overweight |
| 2022-03-02 | 재개 | Cowen | Outperform |
| 2021-04-12 | 개시 | Piper Sandler | Overweight |
| 2021-03-01 | 개시 | Stifel | Buy |
| 2021-02-26 | 재확인 | H.C. Wainwright | Buy |
| 2020-03-10 | 개시 | The Benchmark Company | Buy |
| 2019-01-17 | 업그레이드 | First Analysis Sec | Neutral → Outperform |
| 2018-05-16 | 개시 | Stephens | Overweight |
| 2017-10-13 | 재확인 | H.C. Wainwright | Buy |
| 2017-05-31 | 개시 | Jefferies | Buy |
| 2017-01-26 | 다운그레이드 | First Analysis Sec | Overweight → Equal-Weight |
| 2017-01-04 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2016-01-06 | 개시 | H.C. Wainwright | Buy |
모두보기
Codexis Inc 주식(CDXS)의 최신 뉴스
Millennium Management LLC Has $171,000 Position in Codexis, Inc. (NASDAQ:CDXS) - Defense World
Bank of America Corp DE Has $364,000 Holdings in Codexis, Inc. (NASDAQ:CDXS) - Defense World
Squarepoint Ops LLC Has $253,000 Position in Codexis, Inc. (NASDAQ:CDXS) - Defense World
Investor Network: Codexis, Inc. to Host Earnings Call - ACCESS Newswire
Two Sigma Investments LP Buys 6,397 Shares of Codexis, Inc. (NASDAQ:CDXS) - Defense World
Codexis at Jefferies Global Healthcare Conference: Enzymatic Synthesis Insights By Investing.com - Investing.com Canada
ProShare Advisors LLC Has $127,000 Stake in Codexis, Inc. (NASDAQ:CDXS) - Defense World
Deutsche Bank AG Raises Holdings in Codexis, Inc. (NASDAQ:CDXS) - Defense World
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $218,000 Stock Position in Codexis, Inc. (NASDAQ:CDXS) - Defense World
Top 5 Synthetic Biology Public Companies (June 2025) - Securities.io
Opaleye Management Makes a Bold Move with Massive Codexis Stock Purchase - TipRanks
Group One Trading LLC Buys Shares of 15,226 Codexis, Inc. (NASDAQ:CDXS) - Defense World
Codexis, Inc. (NASDAQ:CDXS) Stake Lifted by Northern Trust Corp - Defense World
Codexis’ Landmark Presentations at TIDES USA Highlight - GlobeNewswire
Transcript : Codexis, Inc.Special Call - marketscreener.com
Codexis (CDXS) Showcases Innovations in siRNA Manufacturing at T - GuruFocus
Codexis (CDXS) Showcases Innovations in siRNA Manufacturing at TIDES USA | CDXS Stock News - GuruFocus
Codexis Highlights Advancements in Eco Synthesis Technology for siRNA Manufacturing at TIDES USA Conference - Nasdaq
Codexis’ Landmark Presentations at TIDES USA Highlight Reproducibility and Process Simplification of the ECO Synthesis Platform for Manufacturing siRNA - GlobeNewswire
Codexis’ Landmark Presentations at TIDES USA Highlight Reproducibility and Process ... - Bluefield Daily Telegraph
Codexis’ Landmark Presentations at TIDES USA Highlight Reproducibility and Process Simplification of the ECO Synthesis Platform for Manufacturing siRNA - GlobeNewswire Inc.
Codexis to Participate in Jefferies Global Healthcare Conference - GuruFocus
Codexis to Participate in Jefferies Global Healthcare Conference | CDXS Stock News - GuruFocus
Argan Strengthens Board with Energy Giant Sempra Executive: Strategic Growth Move - Stock Titan
Codexis’s SWOT analysis: innovative enzyme firm’s stock poised for growth - Investing.com Australia
Codexis’s SWOT analysis: innovative enzyme firm’s stock poised for growth By Investing.com - Investing.com Canada
Former Genentech and Codexis Legal Leader Takes Top Legal Role at Liver Disease Biotech Aligos - Stock Titan
Codexis, Inc. (NASDAQ:CDXS) Shares Bought by Ameriprise Financial Inc. - Defense World
Cantor Fitzgerald Lowers Earnings Estimates for Codexis - Defense World
Codexis (NASDAQ:CDXS) Stock Rating Upgraded by StockNews.com - Defense World
Price T Rowe Associates Inc. MD Boosts Stock Position in Codexis, Inc. (NASDAQ:CDXS) - Defense World
Codexis, Inc. (NASDAQ:CDXS) Just Released Its First-Quarter Earnings: Here's What Analysts Think - Yahoo Finance
Codexis, Inc. (NASDAQ:CDXS) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates - simplywall.st
Codexis, Inc. (NASDAQ:CDXS) Q1 2025 Earnings Call Transcript - Insider Monkey
Codexis, Inc. (NASDAQ:CDXS) Shares Sold by Stifel Financial Corp - Defense World
Codexis Earnings Call: Strategic Growth Amid Challenges - TipRanks
Codexis reiterates $64M-$68M 2025 revenue guidance as ecosynthesis platform gains traction with CDMOs - MSN
Stifel maintains Buy rating on Codexis stock with $5 target By Investing.com - Investing.com India
Stifel maintains Buy rating on Codexis stock with $5 target - Investing.com
Codexis May 2025 presentation slides: RNA manufacturing pivot targets path to profitability - Investing.com Canada
Codexis Inc (CDXS) Q1 2025 Earnings Call Highlights: Navigating Revenue Volatility with Strategic Growth Initiatives - GuruFocus
Codexis Inc (CDXS) Q1 2025 Earnings: EPS at -$0.23 and Revenue H - GuruFocus
Codexis Inc (CDXS) Q1 2025 Earnings Call Highlights: Navigating Revenue Volatility with ... - Yahoo Finance
Codexis Reports Q1 2025 Financial Results and Strategic Progress - TipRanks
Codexis: Q1 Earnings Snapshot - MySA
Earnings call transcript: Codexis Q1 2025 results miss forecasts, stock declines - Investing.com Nigeria
Codexis (CDXS) Navigates Q1 Revenue Challenges, Confirms 2025 Ou - GuruFocus
Codexis, Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:CDXS) - Seeking Alpha
Codexis (CDXS) Projects Financial Stability Until 2026 | CDXS St - GuruFocus
Codexis (CDXS) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Codexis Inc (CDXS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Codexis Inc 주식 (CDXS) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Opaleye Management Inc. | 10% Owner |
May 28 '25 |
Buy |
2.36 |
5,000 |
11,800 |
12,000,000 |
| Opaleye Management Inc. | 10% Owner |
Apr 30 '25 |
Buy |
2.31 |
25,000 |
57,660 |
9,655,000 |
| Opaleye Management Inc. | 10% Owner |
May 01 '25 |
Buy |
2.32 |
20,000 |
46,436 |
9,675,000 |
| Opaleye Management Inc. | 10% Owner |
Apr 25 '25 |
Buy |
2.24 |
25,000 |
55,915 |
9,630,000 |
| Opaleye Management Inc. | 10% Owner |
Apr 16 '25 |
Buy |
2.13 |
70,000 |
148,890 |
9,560,000 |
| Opaleye Management Inc. | 10% Owner |
Apr 17 '25 |
Buy |
2.09 |
45,000 |
94,162 |
9,605,000 |
| Opaleye Management Inc. | 10% Owner |
Apr 15 '25 |
Buy |
2.23 |
25,000 |
55,720 |
9,490,000 |
| Opaleye Management Inc. | 10% Owner |
Apr 08 '25 |
Buy |
1.98 |
100,000 |
198,380 |
9,465,000 |
| Opaleye Management Inc. | 10% Owner |
Apr 03 '25 |
Buy |
2.30 |
75,000 |
172,740 |
9,365,000 |
| Opaleye Management Inc. | 10% Owner |
Apr 01 '25 |
Buy |
2.48 |
35,000 |
86,772 |
9,285,000 |
1.91%
1.17%
자본화:
|
볼륨(24시간):